An increasing number of pharma companies are going ‘beyond the pill’ to improve health outcomes for neurological diseases. GlobalData identified three highlights for the neurology market.
The approval of Abilify MyCite represents a new breed of digital innovation. This is the first FDA-approved drug with a digital ingestion tracking system, essentially a drug-device combination of the antipsychotic Abilify (aripiprazole) embedded with Proteus’ ingestible sensor. The sensor is the size of a grain of sand, and made of silicon, copper and magnesium. When ingested, the stomach acid activates a small electrical signal that is picked up by the wearable MyCite Patch placed on the ribcage, and in turn, this sends information via Bluetooth to a smartphone application, the MyCite App. In this way, dosing, adherence to medication, activity levels, sleeping patterns, steps taken, and heart rate can all be monitored. Compliance is a notable challenge for patients taking antipsychotics, and Abilify MyCite aims to address this unmet need.
Novartis launched an app-based study for multiple sclerosis patients, collecting data remotely via their smartphones. The study, Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS), is designed to collect sensor-based movement data, symptoms, and functional performance tasks. GlobalData believes the real world data collected from this study has the potential to improve understanding of disease progression and monitor treatment effectiveness.
Takeda and Lundbeck are planning to test an app to track and measure patients’ experience on antidepressant therapies. During the 12-week study, patients will be able to record medications, moods, side effects, medication adherence, and facilitate communication with physicians. GlobalData expects this app can help tailor treatment approaches and improve health outcomes for depression patients.